U.S. flag

An official website of the United States government

NM_000116.5(TAFAZZIN):c.238+10C>A AND 3-Methylglutaconic aciduria type 2

Germline classification:
Likely benign (1 submission)
Last evaluated:
Dec 8, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003622430.2

Allele description [Variation Report for NM_000116.5(TAFAZZIN):c.238+10C>A]

NM_000116.5(TAFAZZIN):c.238+10C>A

Gene:
TAFAZZIN:tafazzin, phospholipid-lysophospholipid transacylase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq28
Genomic location:
Preferred name:
NM_000116.5(TAFAZZIN):c.238+10C>A
HGVS:
  • NC_000023.11:g.154412224C>A
  • NG_009634.2:g.5690C>A
  • NG_012884.2:g.4865G>T
  • NM_000116.5:c.238+10C>AMANE SELECT
  • NM_001303465.2:c.292+10C>A
  • NM_001410698.1:c.292+10C>A
  • NM_181311.4:c.238+10C>A
  • NM_181312.4:c.238+10C>A
  • NM_181313.4:c.238+10C>A
  • LRG_131t1:c.238+10C>A
  • LRG_131:g.5690C>A
  • NC_000023.10:g.153640561C>A
Molecular consequence:
  • NM_000116.5:c.238+10C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001303465.2:c.292+10C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001410698.1:c.292+10C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_181311.4:c.238+10C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_181312.4:c.238+10C>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_181313.4:c.238+10C>A - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
3-Methylglutaconic aciduria type 2 (BTHS)
Synonyms:
Barth syndrome; 3-methylglutaconicaciduria type II; MGA type II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010543; MedGen: C0574083; Orphanet: 111; OMIM: 302060

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV004395206Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Likely benign
(Dec 8, 2022) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004395206.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024